Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.
Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Gareen I, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C. Lehman CD, et al. Among authors: solin lj. JAMA Oncol. 2019 Jul 1;5(7):1036-1042. doi: 10.1001/jamaoncol.2018.6269. JAMA Oncol. 2019. PMID: 30653209 Free PMC article. Clinical Trial.
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Solin LJ, et al. Breast Cancer Res Treat. 2012 Jul;134(2):683-92. doi: 10.1007/s10549-012-2072-y. Epub 2012 May 1. Breast Cancer Res Treat. 2012. PMID: 22547108 Free PMC article.
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.
Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ. Rakovitch E, et al. Among authors: solin lj. Breast Cancer Res Treat. 2018 Jun;169(2):359-369. doi: 10.1007/s10549-018-4693-2. Epub 2018 Jan 31. Breast Cancer Res Treat. 2018. PMID: 29388015 Free PMC article.
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ. Tevaarwerk AJ, et al. Among authors: solin lj. J Clin Oncol. 2014 Dec 10;32(35):3948-58. doi: 10.1200/JCO.2014.55.6993. Epub 2014 Oct 27. J Clin Oncol. 2014. PMID: 25349302 Free PMC article. Clinical Trial.
Reply to C. Shah et al.
Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Solin LJ, et al. J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001578 No abstract available.
237 results